mRNA non-vaccine therapeutics set to reach $2 billion in sales by 2028

Although at present there are no messenger RNA (mRNA) non-vaccine therapeutics on the market, this landscape will reach a total of five marketed products by 2028, generating over $2 billion in revenue across the seven major markets (7MM), says data and analytics company GlobalData.

There has been a surge of interest in the mRNA therapeutics space following the COVID-19 pandemic wherein mRNA vaccines proved successful. mRNA is a single-stranded ribonucleic acid that is transcribed from a strand of DNA and carries the coding information for protein synthesis. mRNA therapeutics thus involve the delivery of in-vitro transcribed mRNA into a target cell in order to induce expression of a specific protein, according to GlobalData’s recent report, ‘ mRNA Therapeutics – Thematic Intelligence’.

Among leaders in the field, Moderna (Nasdaq: MRNA), Ultragenyx Pharmaceuticals (Nasdaq: RARE), Omega Therapeutics (Nasdaq: OMGA), and BioNTech (Nasdaq: BNTX) are exploring non-vaccine mRNA therapeutics for cancer and rare genetic diseases.